A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
A phase 2 trial of Trastuzumab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC is a phase 2 interventional study registered as NCT05246514 by AstraZeneca, with 72 participants enrolled, started 2022-07-13 and due to reach its primary completion in 2024-11-04. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: HER2-mutant Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Trastuzumab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Trastuzumab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Shares Trastuzumab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Shares Trastuzumab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonBob T. Li